Sucampo Pharmaceuticals (NASDAQ: SCMP) shares declined on Tuesday, a move tied to a downgrade by analysts at Maxim. In response ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE